Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease

Archives of Internal Medicine

Volumn 163, Issue 9, 2003, Pages 1069-1075

  Tzourio, Christophe ^b   Anderson, Craig ^b   Chapman, Neil ^b   Woodward, Mark ^b   Neal, Bruce ^b   MacMahon, Stephen ^b   Chalmers, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDAPAMIDE; PERINDOPRIL; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR DISORDERS; COGNITION; COGNITION DISORDERS; DEMENTIA; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; PERINDOPRIL; RISK; TREATMENT OUTCOME;

EID: 0038669268     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.9.1069     Document Type: Article

References (30)

1. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press; 1996.
2. Skoog I, Lernfelt B, Landahl S, et al. 15-Year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-1145.
3. Launer L, Masaki K, Petrovitch H, Foley D, Havlik R. The association between midlife blood pressure levels and late-life cognitive function. JAMA. 1995;274:1846-1851.
4. Kilander L, Nyman H, Boberg J, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31:780-786.
5. Tzourio C, Dufouil C, Ducimetiere P, Alpérovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. Neurology. 1999; 53:1948-1952.
6. Tatemichi T, Paik M, Bagiella E, et al. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology. 1994;44:1885-1891.
7. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Dementia three months after stroke: baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke. 1997;28:785-792.
8. Kokmen E, Whisnant J, O'Fallon W, Chu C, Beard C. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology. 1996; 46:154-159.
9. Skoog I. The relationship between blood pressure and dementia: a review. Biomed Pharmacother. 1997;51:367-375.
10. Kivipelto M, Helkala E, Laakso M, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322:1447-1451.
11. Hofman A, Ott A, Breteler M, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997; 349:151-154.
12. Snowdon D, Greiner L, Mortimer J, Riley K, Greiner P, Markesbery W. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA. 1997;277:813-817.
13. Skoog I. The interaction between vascular disorders and Alzheimer's disease. In: Iqbal K, Swaab DF, Winblad B, Wisniewski HM, eds. Alzheimer's Disease and Related Disorders: Etiology, Pathogenesis and Therapeutics. Chichester, England: John Wiley & Sons Ltd; 1999:523-530.
14. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
15. Prince M, Bird A, Blizard R, Mann A. Is the cognitive function of older patients affected by antihypertensive treatment? results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ. 1996;312:801-805.
16. Forette F, Seux M, Staessen J, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.
17. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens. 1996;14(suppl 2):S41-S46.
18. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
19. Hixson J, Vernier D. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res. 1990;31:545-548.
20. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
21. Tzourio C, Anderson C, for the PROGRESS Management Committee. Blood pressure reduction and risk of dementia in patients with stroke: rationale of the dementia assessment in PROGRESS (Perindopril Protection Against Recurrent Stroke Study). J Hypertens. 2000;18(suppl 1):S21-S24.
22. The American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
23. Yaffe K, Lui L, Grady D, Cauley J, Kramer J, Cummings S. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 2000; 356:708-712.
24. Dufouil C, Tzourio C, Brayne C, Berr C, Amouyel P, Alpérovitch A. Influence of Apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers: the EVA Study. Epidemiology. 2000;11:280-284.
25. Ott A, Breteler M, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia: the Rotterdam Study. Am J Epidemiol. 1998;147:574-580.
26. Launer L, Anderson K, Dewey M, et al, and the EURODEM Incidence Research Group and Work Groups. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. Neurology. 1999;52:78-84.
27. PROGRESS Management Committee. PROGRESS (Perindopril Protection Against Recurrent Stroke Study) characteristics of the study population at baseline. J Hypertens. 1999;17:1647-1655.
28. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-839.
29. Di Bari M, Pahor M, Franse L, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. Am J Epidemiol. 2001;153:72-78.
30. Hachinski V. Preventable senility: a call for action against the vascular dementias. Lancet. 1992;340:645-648.